Zhongke Huayi Secures Pre-A and Pre-A+ Funding Rounds, Advances Non-Invasive Neuromodulation Platform

Investment Circle (ID: pedaily2012) November 25th, News: NeurPlus (Shenzhen NeurPlus Technology Co., Ltd.) announced the successful completionTens of Millions of RMBPre-AWheel andPre-A+Round of FinancingAccording to Qichacha information, the Pre-A round was led byTaiyu Investment, Zhongke AngelInvestment; Pre-A+ bySeven Seas CapitalAndLinchuang Sinan FundParticipate together.

The funds from this financing will be mainly used to accelerate the market expansion of non-invasive neuromodulation products such as transcranial electrical stimulators that have already been approved, as well as to develop new product pipelines, advance clinical trials, and expand the team.

NeurPlusIncubated by the Brain Institute of Shenzhen Advanced Institute of Chinese Academy of Sciences,An innovative medical technology enterprise dedicated to the prevention, treatment, and rehabilitation of various brain functional disorders through non-pharmacological physical neuromodulation methods. The company's core technology stems from our years of accumulation in the field of brain science technology research and development. NeurPlus continues to focus on advancing key underlying technologies such as non-invasive neural stimulation positioning optimization algorithms, closed-loop adjustment algorithms, integrated multi-channel stimulation chip technology, and electrode interface materials. To date, the company has obtained more than 10 patents related to brain-computer interfaces and neuromodulation. In the non-pharmacological treatment research of neurological and psychiatric disorders such as cognitive impairment and Alzheimer’s disease, coma awakening, depression, and epilepsy, NeurPlus has established close collaborations with multiple Class A tertiary hospitals across China.